Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

Adicet Bio (ACET) , a clinical-stage company, develops “off-the-shelf” gamma delta T cell therapies with novel mechanisms of action for patients with cancer and autoimmune diseases.The company’s lead product candidate, ADI-001, is an investigational allogeneic gamma delta CAR T cell therapy targeting CD20. It is currently being evaluated in a phase I study for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.Over the past month, shares of Adicet have skyrocketed 130.4% compar ...